1124P Lenvatinib + pembrolizumab (L + P) in participants (Pts) with advanced or recurrent endometrial cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. - Marth, C.; Lorusso, D.; Bidzinski, M.; Salutari, V.; Akıllı, H.; Oaknin, A.; Kaen, D.L.; Nogueira-Rodrigues, A.; Miller, D.S.; Hasegawa, K.; Mackay, H.; Moore, R.G.; et al. (Annals of Oncology, 2025)